153 related articles for article (PubMed ID: 23200915)
1. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.
Ivan C; Hu W; Bottsford-Miller J; Zand B; Dalton HJ; Liu T; Huang J; Nick AM; Lopez-Berestein G; Coleman RL; Baggerly KA; Sood AK
Gynecol Oncol; 2013 Mar; 128(3):506-11. PubMed ID: 23200915
[TBL] [Abstract][Full Text] [Related]
2. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis.
Agustriawan D; Huang CH; Sheu JJ; Lee SC; Tsai JJP; Kurubanjerdjit N; Ng KL
Comput Biol Chem; 2016 Dec; 65():154-164. PubMed ID: 27746113
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
5. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
Liu F; Zhang G; Lv S; Wen X; Liu P
J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
[TBL] [Abstract][Full Text] [Related]
6. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
7. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
[TBL] [Abstract][Full Text] [Related]
8. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
9. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
10. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
11. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
13. TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.
Braga Lda C; Alvares da Silva Ramos AP; Traiman P; Silva LM; Lopes da Silva-Filho A
Gynecol Oncol; 2012 Aug; 126(2):268-73. PubMed ID: 22555108
[TBL] [Abstract][Full Text] [Related]
14. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
Zhou X; Teng L; Wang M
Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
[TBL] [Abstract][Full Text] [Related]
17. Poor survival with wild-type TP53 ovarian cancer?
Wong KK; Izaguirre DI; Kwan SY; King ER; Deavers MT; Sood AK; Mok SC; Gershenson DM
Gynecol Oncol; 2013 Sep; 130(3):565-9. PubMed ID: 23800698
[TBL] [Abstract][Full Text] [Related]
18. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
Dwivedi SK; Mustafi SB; Mangala LS; Jiang D; Pradeep S; Rodriguez-Aguayo C; Ling H; Ivan C; Mukherjee P; Calin GA; Lopez-Berestein G; Sood AK; Bhattacharya R
Oncotarget; 2016 Mar; 7(12):15093-104. PubMed ID: 26918603
[TBL] [Abstract][Full Text] [Related]
20. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]